The FDA authorized an Expanded Access Program for NAI to manage lymphopenia in refractory or relapsed solid tumor patients. ImmunityBio’s Cancer BioShield platform enhances NK and T cell proliferation ...

Panelists discuss the expanding treatment options for BCG-unresponsive high-risk non–muscle-invasive bladder cancer, highlighting the benefits and limitations of FDA-approved therapies like ...

Non-Hispanic Black and Latinx patients with prostate cancer are less likely to receive PSMA-PET imaging than non-Hispanic White patients, indicating racial/ethnic disparities. The study analyzed 550 ...

Prostate cancer awareness is crucial year-round, emphasizing screening and meaningful conversations about risk and prevention. Screening guidelines vary, focusing on shared decision-making and ...

EV+P demonstrated superior efficacy to chemotherapy across all specified subgroups assessed. The phase 3 EV-302 trial (NCT04223856) showed that the combination of enfortumab vedotin plus pembrolizumab ...

Panelists discuss the evolving definition of BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), emphasizing its critical role in identifying patients who fail adequate BCG therapy, guiding ...

Zanzalintinib and nivolumab showed a 63% response rate and 18.5-month median PFS in stage 4 RCC. The study included patients with advanced RCC, treated with zanzalintinib plus nivolumab or ...

Paul E. Dato, MD, discusses how bone-targeted therapies play an important supportive role in advanced prostate cancer, with recommendations for calcium and vitamin D supplementation, vitamin K2 ...

Jack Andrews, MD; Eugene Cone, MD; and Akshay Sood, MD, discuss how real-world safety and efficacy data for androgen receptor inhibitors (apalutamide, darolutamide, and enzalutamide) in nonmetastatic ...

BCG plus mitomycin demonstrated similar efficacy and safety to BCG alone, with fewer treatment discontinuations and reduced BCG doses in NMIBC patients. The combination therapy showed a 40% reduction ...

“There are a lot of variables and factors in deciding what might be the entire first-line of therapy," says Adam B. Weiner, MD. The cornerstone for first-line treatment in metastatic prostate cancer ...

Paul E. Dato, MD, discusses how treatment selection between triplet therapy, doublet therapy, or androgen deprivation monotherapy should be based on disease volume, risk factors, patient age, fitness ...